Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody–drug conjugate, demonstrates in vitro and in vivo antitumor activity against primary and metastatic ovarian tumors overexpressing HER2

Levent Mutlu; Blair McNamara; Stefania Bellone; Diego D. Manavella; Cem Demirkiran; Michelle Greenman; Miguel Skyler Z. Verzosa; Natalia Buza; Pei Hui; Tobias Max Philipp Hartwich; Justin Harold; Yang Yang-Hartwich; Margherita Zipponi; Gary Altwerger; Elena Ratner; Gloria S. Huang; Mitchell Clark; Vaagn Andikyan; Masoud Azodi; Peter E. Schwartz; Alessandro D. Santin